|
1
|
Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, Taddei K, Gardener S, Masters CL, Schofield PR, Multhaup G, Benzinger TLS, Morris JC, Bateman RJ, Greenberg SM, van Buchem MA, Stoops E, Vanderstichele H, Teunissen CE, Hankey GJ, Wermer MJH, Sohrabi HR, Martins RN. Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. Int J Mol Sci 2021; 22:ijms22062931. [PMID: 33805778 PMCID: PMC8000178 DOI: 10.3390/ijms22062931] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 03/06/2021] [Accepted: 03/07/2021] [Indexed: 01/10/2023] Open
Abstract
Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2) and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates, at both T1(Aβ1-40: p = 0.001; Aβ1-42: p = 0.0004) and T2 (Aβ1-40: p = 0.001; Aβ1-42: p = 0.016) employing the Single Molecule Array (Simoa) platform, however no significant differences were observed using the xMAP platform. Further, pairwise longitudinal analyses of plasma Aβ1-40 revealed decreased levels in MCs using data from the Simoa platform (p = 0.041) and pairwise longitudinal analyses of plasma Aβ1-42 revealed decreased levels in MCs using data from the xMAP platform (p = 0.041). Findings from the Simoa platform suggest that plasma Aβ may add value to a panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further validation studies in larger sample sets are required.
Collapse
Affiliation(s)
- Pratishtha Chatterjee
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Michelle Tegg
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Steve Pedrini
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Anne M. Fagan
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Chengjie Xiong
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
- Division of Biostatistics, Washington University, St. Louis, MO 63130, USA
| | - Abhay K. Singh
- Macquarie Business School, Macquarie University, North Ryde, NSW 2109, Australia;
| | - Kevin Taddei
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
| | - Samantha Gardener
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia;
| | - Peter R. Schofield
- Neuroscience Research Australia, Sydney, NSW 2031, Australia;
- School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia
| | - Gerhard Multhaup
- Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada;
| | - Tammie L. S. Benzinger
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
- Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - John C. Morris
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Randall J. Bateman
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Steven M. Greenberg
- Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, MA 02114, USA;
| | - Mark A. van Buchem
- Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
| | | | | | - Charlotte E. Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, 1007 MB Amsterdam, The Netherlands;
| | - Graeme J. Hankey
- Faculty of Health and Medical Sciences, Medical School, The University of Western Australia, Crawley, WA 6009, Australia;
| | - Marieke J. H. Wermer
- Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
| | - Hamid R. Sohrabi
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
- Centre for Healthy Ageing, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, WA 6150, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia
| | - Ralph N. Martins
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia
- The KaRa Institute of Neurological Disease, Macquarie Park, NSW 2113, Australia
- Correspondence: ; Tel.: +61-8-6304-5456; Fax: +61-8-6304-5851
| | | |
Collapse
|
|
2
|
Montañola A, de Retana SF, López-Rueda A, Merino-Zamorano C, Penalba A, Fernández-Álvarez P, Rodríguez-Luna D, Malagelada A, Pujadas F, Montaner J, Hernández-Guillamon M. ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy. Neuromolecular Med 2015; 18:99-108. [PMID: 26661731 DOI: 10.1007/s12017-015-8381-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Accepted: 11/17/2015] [Indexed: 01/26/2023]
Abstract
The involvement of apolipoproteins, such as the ApoE4 isoform, in Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) highlights the fact that certain lipid carriers may participate in soluble β-amyloid (Aβ) transport. Our general aim was to characterize the soluble levels of the apolipoproteins apoE, apoA1 and apoJ/clusterin and their genotype status in patients with CAA. We analyzed the genotypes frequency of APOA1 (rs5069, rs670), CLU (rs11136000, rs1532278, rs7012010, rs9331888) and APOE (rs429358, rs7412) in a cohort of patients with CAA-associated intracerebral hemorrhage (ICH) (n = 59) and compared the results with those from hypertension-associated ICH (n = 42), AD patients (n = 73) and controls (n = 88). In a subgroup of patients, we also determined the plasma concentrations of apoE, apoA1 and apoJ/clusterin. We found increased plasma apoJ/clusterin levels in CAA patients compared to AD patients or controls after adjusting for sex and age (CAA vs. controls, p = 0.033; CAA vs. AD, p = 0.013). ApoA1 levels were not altered between groups, although a strong correlation was observed between plasma Aβ(1-40) and apoA1 among CAA patients (r = 0.583, p = 0.007). Regarding plasma apoE concentration, a robust association between circulating levels and genotype status was confirmed (p < 0.001). Whereas the APOE4 frequency was higher in AD (p < 0.001) and CAA (p = 0.013), the APOA1 and CLU genotypes were not different among groups. In the CAA cohort, the risk-linked CLU variant (C) rs11136000 was associated with white matter hyperintensities (p = 0.045) and the presence of lobar microbleeds (p = 0.023) on MRI. In summary, our findings suggest that apoA1 may act as a physiological transporter of Aβ(1-40) and that apoJ/clusterin appears to be a chaperone related to distinctive lesions in CAA brains.
Collapse
Affiliation(s)
- Alex Montañola
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Sofía Fernández de Retana
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Antonio López-Rueda
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Cristina Merino-Zamorano
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Anna Penalba
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | | | - David Rodríguez-Luna
- Neurovascular Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain
| | - Ana Malagelada
- Dementia Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain
| | - Francesc Pujadas
- Dementia Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain
| | - Joan Montaner
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain
- Neurovascular Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain
| | - Mar Hernández-Guillamon
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
| |
Collapse
|